Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs

Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs

Authors

  • Preslav Vasilev Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University - Pleven, Bulgaria
  • Savelina Popovska Department of General and Clinical Pathology, Faculty of Medicine, Medical University-Pleven, Bulgaria
  • Elitsa Petrova Kraevska Department of General and Clinical Pathology, Faculty of Medicine, Medical University-Pleven, Bulgaria
  • Martin Karamanliev Surgical Oncology Department, University Hospital “Dr. Georgi Stranski”, Faculty of Medicine, Medical University-Pleven, Bulgaria
  • Dobromir Dimitrov Surgical Oncology Department, University Hospital “Dr. Georgi Stranski”, Faculty of Medicine, Medical University-Pleven, Bulgaria
  • Ivelina Yordanova Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University-Pleven, Bulgaria

Keywords:

squamous cell carcinoma of the skin, PD-L1, PD-1, CD8, High-risk clinicopathological factors

Abstract

Introduction:  Squamous cell carcinoma of the skin (SCCs) is the second most common skin cancer with continuously increasing incidence. Programmed cell death ligand 1 (PD-L1), Programmed cell death 1 receptor (PD-1) and CD8 expression in primary SCCs has not been described in many studies.

Objective: We investigated the association between PD-L1, PD-1, CD8 and clinocopathological prognostic factors for recurrence, metastasis and mortality of SCCs.

Patients and Methods: Immunohistochemically stained sections of 100 primary SCCs divided in two groups according to diameter of the tumors (<20 mm and >20mm) were assessed. Recombinant rabbit Anti-PD-L1 antibody [SP142] - C-terminal, rabbit monocloncal Anti-PD1 antibody [NAT105] and FLEX Mono Mo a Hu CD8, cl C8/144B, RTU were used.

Results: We did not establish statistically significant differences between PD-L1, PD-1, CD8 expression and high-risk clinocopathological features – tumor size >20mm, depth >6mm, poor tumor cell differentiation, perineural/lymphovascular invasion, low/absent lymphocyte stromal reaction. 

Conclusions: In primary SCCs, the expression of PD-L1, PD-1 and CD8 is not associated with high-risk clinicopathological factors. We suggest that these immunohistochemical markers are more significant in advanced cases and metastatic tissues.

References

Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: from biology to therapy. Int J Mol Sci. 2020;21(8):2956. 2.Muzic JG, Schmitt AR, Wright AC, Alniemi DT, Zubair AS, Olazagasti Lourido JM et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017;92(6):890-898.

Amoils M, Lee CS, Sunwoo J, et al. Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head Neck. 2017 May;39(5):881-885. doi: 10.1002/hed.24692. Epub 2017 Mar 2. PMID: 28252823.

Sabbatino F, Marra A, Liguori L, et al. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. J Immunother Cancer. 2018 Nov 20;6(1):126. doi: 10.1186/s40425-018-0439-2. PMID: 30458852; PMCID: PMC6247622.

García-Pedrero JM, Martínez-Camblor P, Diaz-Coto S, et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol. 2017 Sep;77(3):527-533. doi: 10.1016/j.jaad.2017.05.047. Epub 2017 Jul 14. PMID: 28716437.

Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. doi: 10.1038/s41571-021-00473-5. Epub 2021 Feb 12. PMID: 33580222.

Aru B, Soltani M, Pehlivanoglu C, et al. Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. Front Oncol. 2022 Jan 27;12:789728. doi: 10.3389/fonc.2022.789728. PMID: 35155232; PMCID: PMC8829140.

Andersen MH, Sørensen RB, Brimnes MK, et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest. 2009 Aug;119(8):2245-56. doi: 10.1172/jci38739. PMID: 19662679; PMCID: PMC2719937.

Kyrgidis A, Tzellos TG, Kechagias N, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010 Jun;46(9):1563-72. doi: 10.1016/j.ejca.2010.02.046. Epub 2010 Mar 24. PMID: 20338745.

S. Wang, J. Li, J. Xie, et al., “Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway,” Oncogene, vol. 37, no. 30, pp. 4164–4180, 2018.

Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016 Aug 12;9:5023-39. doi: 10.2147/OTT.S105862. PMID: 27574444; PMCID: PMC4990391.

Katsuya Y, Fujita Y, Horinouchi H, et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015 May;88(2):154-9. doi: 10.1016/j.lungcan.2015.03.003. Epub 2015 Mar 10. PMID: 25799277.

Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18. PMID: 25695955.

Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in Tumor Microenvironment. Comput Struct Biotechnol J. 2018 Nov 22;17:1-13. doi: 10.1016/j.csbj.2018.11.004. PMID: 30581539; PMCID: PMC6297055.

Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol. 2014 Jun;96(3):284-91. doi: 10.1016/j.yexmp.2014.03.005. Epub 2014 Mar 20. PMID: 24657498.

Chen L, Deng H, Lu M, et al. B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. Int J Clin Exp Pathol. 2014 Aug 15;7(9):6015-23. PMID: 25337246; PMCID: PMC4203217.

Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6(9):e23621. doi: 10.1371/journal.pone.0023621. Epub 2011 Sep 1. PMID: 21912640; PMCID: PMC3164659.

Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. doi: 10.1158/1078-0432.CCR-06-1868. PMID: 17255298.

Zhang Y, Kang S, Shen J, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. Medicine (Baltimore). 2015 Feb;94(6):e515. doi: 10.1097/MD.0000000000000515. PMID: 25674748; PMCID: PMC4602735.

Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013 Jul;1(1):54-63. doi: 10.1158/2326-6066.CIR-13-0034. PMID: 24416729; PMCID: PMC3885978.

Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014 May 15;20(10):2773-82. doi: 10.1158/1078-0432.CCR-13-2702. Epub 2014 Mar 19. PMID: 24647569.

Lehmer L, Choi F, Kraus C, et al. Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review. Am J Dermatopathol. 2021 May 1;43(5):321-330. doi: 10.1097/DAD.0000000000001772. PMID: 33910221.

Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol. 2016 Aug;43(8):663-70. doi: 10.1111/cup.12728. Epub 2016 Jun 20. PMID: 27153517.

Oh ST, Yang KJ, Lee JU, et al. Differential expression of programmed death-1 according to the histological differentiation of cutaneous squamous cell carcinoma. Br J Dermatol. 2019 Sep;181(3):628-629. doi: 10.1111/bjd.17850. Epub 2019 Jul 10. PMID: 30822360.

Roper E, Lum T, Palme CE, et al. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma. Pathology. 2017 Aug;49(5):499-505. doi: 10.1016/j.pathol.2017.04.004. Epub 2017 Jun 27. PMID: 28666643.

García-Díez I, Hernández-Ruiz E, Andrades E, et al. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. Am J Dermatopathol. 2018 Sep;40(9):647-654. doi: 10.1097/DAD.0000000000001164. Erratum in: Am J Dermatopathol. 2019 Jul;41(7):537. PMID: 29742559.

Varki V, Ioffe OB, Bentzen SM, et al. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunol Immunother. 2018 May;67(5):805-814. doi: 10.1007/s00262-018-2138-8. Epub 2018 Feb 27. PMID: 29484464.

Schaper K, Köther B, Hesse K, et al. The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma. Br J Dermatol. 2017 May;176(5):1354-1356. doi: 10.1111/bjd.14955. Epub 2017 Mar 8. PMID: 27516151.

Downloads

Published

2024-07-31

How to Cite

1.
Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs. Dermatol Pract Concept [Internet]. 2024 Jul. 31 [cited 2024 Dec. 5];14(3):e2024176. Available from: https://www.dpcj.org/index.php/dpc/article/view/4147

Share